Skip to main content

Longboard Pharmaceuticals, Inc. — key financial figures for fiscal year 2023 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Net Income/Loss (FY2023)
-$54.4M
Total Assets (FY2023)
$50.7M
Total Equity (FY2023)
$40.9M
Cash Flows from Operating Activities (FY2023)
-$50.9M

Source: Longboard Pharmaceuticals, Inc. 10-K filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.

Discover Hub-Equity